Coordinated proteomic signature changes in immune response and complement proteins in acute myocardial infarction: The implication of serum amyloid P-component

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5196-5204

  Cubedo, Judit ^a,d   Padró, Teresa ^a,b,d   Badimon, Lina ^a,b,c,d  

^a Institut Català de Ciències Cardiovasculars   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

Acute myocardial infarction; Acute phase response; Complement; Immunity; Inflammation; Proteomics

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALPHA1 GLYCOPROTEIN; AMYLOID P COMPONENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COMPLEMENT; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C3; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FETUIN A; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; SERUM AMYLOID P; TRIACYLGLYCEROL; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART MUSCLE NECROSIS; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUE INJURY;

ACUTE MYOCARDIAL INFARCTION; ACUTE-PHASE RESPONSE; COMPLEMENT; IMMUNITY; INFLAMMATION; PROTEOMICS;

ACUTE-PHASE REACTION; AGED; BIOLOGICAL MARKERS; COMPLEMENT SYSTEM PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NECROSIS; PROGNOSIS; PROTEOMICS; RISK FACTORS; SERUM AMYLOID P-COMPONENT; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84887176495     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.181     Document Type: Article

References (38)

1. I. Kushner, and D. Rzewniki Acute phase response J.I. Gallin, R. Snyderman, Inflammation: basic principles and clinical correlates 3rd ed. 1999 Lippincott Williams & Wilkins Philadelphia
2. A. Tedgui, and Z. Mallat Cytokines in atherosclerosis: pathogenic and regulatory pathways Physiol Rev 86 2006 515 581
3. D.N. Tziakas, G.K. Chalikias, and J.C. Kaski Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach Atherosclerosis 193 2007 196 203
4. M. Padmasekar, R. Nandigama, M. Wartenberg, K.D. Schlüter, and H. Sauer The acute phase protein alpha2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways Cardiovasc Res 75 2007 118 128
5. R. Mariotti, G. Musumeci, and M. De Carlo Acute-phase reactants in acute myocardial infarction: impact on 5-year prognosis Ital Heart J 2 2001 294 300
6. M.N. Zairis, E.N. Adamopoulou, and S.J. Manousakis The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes Atherosclerosis 194 2007 397 402
7. S. Süer Gökmen, C. Kazezoǧlu, and B. Sunar Relationship between serum sialic acids, sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction Clin Chem Lab Med 44 2006 199 206
8. G. Lindberg, G.A. Eklund, B. Gullberg, and L. Råstam Serum sialic acid concentration and cardiovascular mortality BMJ 302 1991 143 146
9. M. Crook, M. Haq, S. Haq, and P. Tutt Plasma sialic acid and acute-phase proteins in patients with myocardial infarction Angiology 45 1994 709 715
10. M.M. Markiewski, B. Nilsson, K.N. Ekdahl, T.E. Mollnes, and J.D. Lambris Complement and coagulation: strangers or partners in crime? Trends Immunol 28 2007 184 192
11. K. Thygesen, J.S. Alpert, and A.S. Jaffe Third universal definition of myocardial infarction Eur Heart J 33 2012 2551 2567
12. E. Wu, R.M. Judd, J.D. Vargas, F.J. Kloche, R.O. Bonow, and R.J. Kim Visualization of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction Lancet 357 2001 21 28
13. J. Cubedo, T. Padró, X. García-Moll, X. Pintó, J. Cinca, and L. Badimon Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction J Proteome Res 10 2011 211 220
14. J. Cubedo, T. Padró, R. Alonso, J. Cinca, P. Mata, and L. Badimon Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk Atherosclerosis 222 2012 263 269
15. O.Y. Kim, M.J. Shin, J. Moon, and J.H. Chung Plasma ceruloplasmin as a biomarker for obesity: a proteomic approach Clin Biochem 44 2011 351 356
16. S. Snyder, E.L. Coodley, B.C. Durham, and R.S. Pennock Serum glycoproteins in coronary artery disease Circulation 56 1977 359 362
17. N. Ishioka, N. Takahashi, and F.W. Putnam Amino acid sequence of human plasma alpha 1B-glycoprotein: homology to the immunoglobulin supergene family Proc Natl Acad Sci U S A 83 1986 2363 2367
18. M. Ombrellino, H. Wang, and H. Yang Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan Shock 15 2001 181 185
19. J. Ren, and A.J. Davidoff Alpha2-Heremans Schmid glycoprotein, a putative inhibitor of tyrosine kinase, prevents glucose toxicity associated with cardiomyocyte dysfunction Diab Metab Res Rev 18 2002 305 310
20. M.W. Merx, C. Schäfer, and R. Westenfeld Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice J Am Soc Nephrol 16 2005 3357 3364
21. O. Bilgir, L. Kebapcilar, and F. Bilgir Decreased serum fetuin-A levels are associated with coronary artery diseases Intern Med 49 2010 1281 1285
22. N. Basar, N. Sen, and S. Kanat Lower fetuin-A predicts angiographic impaired reperfusion and mortality in ST-elevation myocardial infarction J Investig Med 59 2011 816 822
23. D.M. Steel, and A.S. Whitehead The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein Immunol Today 15 1994 81 88
24. M.B. Pepys, M.L. Baltz, and F.C. de Beer Biology of serum amyloid P component Ann N Y Acad Sci 389 1982 286 298
25. S.C. Ying, A.T. Gewurz, H. Jiang, and H. Gewurz Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q J Immunol 150 1993 169 176
26. X.A. Li, K. Hatanaka, H. Ishibashi-Ueda, C. Yutani, and A. Yamamoto Characterization of serum amyloid P component from human aortic atherosclerotic lesions Arterioscler Thromb Vasc Biol 15 1995 252 257
27. N.S. Jenny, A.M. Arnold, L.H. Kuller, R.P. Tracy, and B.M. Psaty Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 27 2007 352 358
28. S. Pervaiz, and K. Brew Homology of beta-lactoglobulin, serum retinol-binding protein, and protein HC Science 228 1985 335 337
29. J.F. Siebel, R.L. Kosinsky, B. Åkerström, and M. Knipp Insertion of heme b into the structure of the Cys34-carbamidomethylated human lipocalin α(1)-microglobulin: formation of a [(heme)(2) (α(1)-Microglobulin)](3) complex Chembiochem 13 2012 879 887
30. W. Meining, and A. Skerra The crystal structure of human α(1)-microglobulin reveals a potential haem-binding site Biochem J 445 2012 175 182
31. P. Májek, Z. Reicheltová, and J. Suttnar Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1 J Transl Med 9 2011 84
32. H. Schäfer, D. Mathey, F. Hugo, and S. Bhakdi Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium J Immunol 137 1986 1945 1949
33. M.M. van Greevenbroek, M. Jacobs, and C.J. van der Kallen Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study) Int J Cardiol 154 2012 158 162
34. I. Ohsawa, H. Inoshita, and M. Ishii Metabolic impact on serum levels of complement component 3 in Japanese patients J Clin Lab Anal 24 2010 113 118
35. K. Yasojima, C. Schwab, E.G. McGeer, and P.L. McGeer Human heart generates complement proteins that are upregulated and activated after myocardial infarction Circ Res 83 1998 860 869
36. H.F. Weisman, T. Bartow, and M.K. Leppo Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis Science 249 1990 146 151
37. C. de Zwaan, A.H. Kleine, and J.H. Diris Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction Eur Heart J 23 2002 1670 1677
38. A. Van Dijk, R.A. Vermond, and P.A. Krijnen Intravenous clusterin administration reduces myocardial infarct size in rats Eur J Clin Invest 40 2010 893 902